Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition
- PMID: 18323528
- PMCID: PMC2793685
- DOI: 10.1161/CIRCRESAHA.107.165936
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition
Abstract
Recent increased adverse cardiovascular events observed with selective cyclooxygenase-2 inhibition led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra), but the mechanisms underlying these atherothrombotic events remain unclear. Prostacyclin is the major end product of cyclooxygenase-2 in vascular endothelium. Using a naturally occurring mutation in the prostacyclin receptor, we report for the first time that a deficiency in prostacyclin signaling through its G protein-coupled receptor contributes to atherothrombosis in human patients. We report that a prostacyclin receptor variant (R212C) is defective in adenylyl cyclase activation in both patient blood and in an in vitro COS-1 overexpression system. This promotes increased platelet aggregation, a hallmark of atherothrombosis. Our analysis of patients in 3 separate white cohorts reveals that this dysfunctional receptor is not likely an initiating factor in cardiovascular disease but that it accelerates the course of disease in those patients with the greatest risk factors. R212C was associated with cardiovascular disease only in the high cardiovascular risk cohort (n=980), with no association in the low-risk cohort (n=2293). In those at highest cardiovascular risk, both disease severity and adverse cardiovascular events were significantly increased with R212C when compared with age- and risk factor-matched normal allele patients. We conclude that for haploinsufficient mutants, such as the R212C, the enhanced atherothrombotic phenotype is likely dependent on the presence of existing atherosclerosis or injury (high risk factors), analogous to what has been observed in the cyclooxygenase-2 inhibition studies or prostacyclin receptor knockout mice studies. Combining both biochemical and clinical approaches, we conclude that diminished prostacyclin receptor signaling may contribute, in part, to the underlying adverse cardiovascular outcomes observed with cyclooxygenase-2 inhibition.
Figures
Similar articles
-
Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease.Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1802-9. doi: 10.1161/ATVBAHA.110.208900. Epub 2010 Jun 3. Arterioscler Thromb Vasc Biol. 2010. PMID: 20522800 Free PMC article.
-
The human prostacyclin receptor from structure function to disease.Prog Mol Biol Transl Sci. 2009;89:133-66. doi: 10.1016/S1877-1173(09)89006-6. Epub 2009 Oct 7. Prog Mol Biol Transl Sci. 2009. PMID: 20374736 Review.
-
Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease.Curr Atheroscler Rep. 2009 May;11(3):227-35. doi: 10.1007/s11883-009-0035-5. Curr Atheroscler Rep. 2009. PMID: 19361355 Review.
-
Prostacyclin, atherothrombosis, and cardiovascular disease.Curr Med Chem. 2007;14(20):2161-9. doi: 10.2174/092986707781389637. Curr Med Chem. 2007. PMID: 17691954 Review.
-
Cardioprotective prostacyclin signaling in vascular smooth muscle.Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):109-18. doi: 10.1016/j.prostaglandins.2006.05.011. Epub 2006 Jul 7. Prostaglandins Other Lipid Mediat. 2007. PMID: 17164138 Review.
Cited by
-
Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Adv Sci (Weinh). 2024 May;11(17):e2308298. doi: 10.1002/advs.202308298. Epub 2024 Feb 17. Adv Sci (Weinh). 2024. PMID: 38368274 Free PMC article. Review.
-
Prostanoids in Cardiac and Vascular Remodeling.Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):558-583. doi: 10.1161/ATVBAHA.123.320045. Epub 2024 Jan 25. Arterioscler Thromb Vasc Biol. 2024. PMID: 38269585 Review.
-
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.Front Med (Lausanne). 2023 Jul 6;10:1198088. doi: 10.3389/fmed.2023.1198088. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37484840 Free PMC article. Review.
-
Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis.J Med Chem. 2023 Jul 27;66(14):9313-9324. doi: 10.1021/acs.jmedchem.3c00655. Epub 2023 Jul 17. J Med Chem. 2023. PMID: 37458373 Free PMC article. Review.
-
The complex genetic basis of fibromuscular dysplasia, a systemic arteriopathy associated with multiple forms of cardiovascular disease.Clin Sci (Lond). 2022 Aug 31;136(16):1241-1255. doi: 10.1042/CS20210990. Clin Sci (Lond). 2022. PMID: 36043395 Free PMC article. Review.
References
-
- Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091. - PubMed
-
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080. - PubMed
-
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102. - PubMed
-
- Drazen JM. COX-2 inhibitors--a lesson in unexpected problems. N Engl J Med. 2005;352:1131–1132. - PubMed
-
- Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539–541. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL34594/HL/NHLBI NIH HHS/United States
- HL074190/HL/NHLBI NIH HHS/United States
- R01 HL074190-04/HL/NHLBI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 HL077612/HL/NHLBI NIH HHS/United States
- CA55075/CA/NCI NIH HHS/United States
- R01 HL074190-02/HL/NHLBI NIH HHS/United States
- R01 HL034594/HL/NHLBI NIH HHS/United States
- HL35464/HL/NHLBI NIH HHS/United States
- R01 HL074190-03/HL/NHLBI NIH HHS/United States
- R01 HL035464/HL/NHLBI NIH HHS/United States
- HL077612/HL/NHLBI NIH HHS/United States
- P30 CA023108/CA/NCI NIH HHS/United States
- R01 HL074190/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials